Rafael Holdings, Inc. — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Rafael Holdings completed Last Patient Last Visit (LPLV) in June 2026 for its Phase 3 TransportNPC trial of Trappsol Cyclo for Niemann-Pick Disease Type C1. A 48-week interim analysis (completed June 2025) showed the independent Data Monitoring Committee recommended continuation through the 96-week final analysis. NDA submission and topline data are expected in the second half of 2026. The company has $30.5M cash and expects to fund operations through multiple value-creating milestones.
Why this rating
Completion of Phase 3 LPLV is pivotal for a $38.6M biotech; NDA pathway near, orphan drug status intact, $920M market potential by 2031. Interim data supportive; near-term catalyst material to valuation.
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.